Stephen V Liu: The 2024 IASLC Global Survey on Biomarker Testing is Available
Stephen V Liu, Chief of Division of Hematology and Oncology at Georgetown Lombardi Comprehensive Cancer Center, Director of Thoracic Oncology and Developmental Therapeutics, shared a post on X:
“Available JTO & JTO CRR – the 2024 International Association for the Study of Lung Cancer (IASLC) Global Survey on Biomarker Testing. Majority (67%) reported most patients had biomarker testing (up from 39% in 2018) but 43% sometimes treated before results. Barriers: cost, time, tissue, access, awareness.”
Balazs Halmos, Associate Director for Clinical Science at Montefiore Einstein Cancer Center, shared a post by Stephen V Liu, adding:
“Biomarker testing – comprehensive AND timely- is so pivotal in the proper management of NSCLC (now advanced and earlier stage alike)
Each team has to train hard for it to deliver the best results for our patients- dropping the baton 43% of the time is unacceptable! But when we get it done right- how exciting it is for the whole relay team – IP/IR/surg-path-mol path- med/rad onc to deliver the Olympic gold of optimal biomarker guided treatment for each patient.”
Title: The 2024 International Association for the Study of Lung Cancer (IASLC) Global Survey on Biomarker Testing
Authors: Matthew P. Smeltzer, Jennifer C. King, Casey Connolly, Kristin Brunson, Maiyan Chau, Shuyan Chen, Anna Kerpel-Fronius, Sylvie Lantuejoul, Anant Mohan, Allison Plaxco, Upal Basu Roy, Ricardo Santos, Ross Soo, Gavitt Woodard, Murry W. Wynes, Yasushi Yatabe, Amanda Young, Karen Kelly
Read the Full Article.
More posts featuring Stephen V Liu and Balazs Halmos.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023